Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NRX2
UPID:
RM17_HUMAN
Alternative names:
39S ribosomal protein L17, mitochondrial; LYST-interacting protein 2
Alternative UPACC:
Q9NRX2; D3DQU3; Q6IAH8; Q96Q53; Q9C066
Background:
The Large ribosomal subunit protein bL17m, also known as 39S ribosomal protein L17, mitochondrial and LYST-interacting protein 2, plays a crucial role in the mitochondrial ribosome. Its involvement in protein synthesis within mitochondria underscores its importance in cellular energy metabolism and overall cellular function.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein bL17m could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis makes it a key target for research aimed at addressing mitochondrial disorders.